Sanofi's vax plant in France preparing to produce 100M doses of dengue vaccine

Sanofi ($SNY) says it is "flipping the model" in its launch of the first approved vaccine to treat dengue. It will submit it for approval in dengue-stricken nations rather than first filing regulatory submissions in the U.S. and Europe. Its vaccine operation, Sanofi Pasteur, has spent 20 years and €1.5 billion on the candidate's development, and, in anticipation of the launch, spent €300 million on a manufacturing facility in 2009 in Neuville-sur-Saône, France, which has the capacity to manufacture 100 million doses annually. It is expected to start production in early 2016. Story | More

Suggested Articles

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

The FDA hit New Jersey-based CMO Tris Pharma with a warning letter, citing significant violations.

Celltrion remains optimistic it will get U.S. approval for its two biosimilar drugs, Rituxan and Herceptin, by the end of the year.